Overall ? The mission of the San Diego Center for AIDS Research (SD CFAR) is to find a cure for HIV for those already infected, and to prevent HIV transmission to those not infected. Our Center?s research priorities are aligned with the NIH Office of AID Research priorities and include: optimizing HIV care, alleviating HIV health disparities and advancing scientific discovery for HIV cure and vaccine efforts.
The specific aims of the SD CFAR are to: 1. Foster innovative HIV research by providing the foundation and framework for highly productive collaborations across disciplines, investigators, member institutions, and the HIV community. 2. Capitalize on our community engagement and international expertise to develop sustainable research programs locally and in targeted low and middle income countries highly impacted by HIV. 3. Provide Training, Inspiration, Mentoring, and Expert guidance (TIME) to local and international investigators across career stages. 4. Thoughtfully plan our Center?s growth and flexibility to adapt to an ever evolving research environment. Structure: The SD CFAR is multi-institutional, with members at La Jolla Institute of Allergy and Immunology (LJI), Sanford Burnham Prebys Medical Discovery Institute (SBP), The Scripps Research Institute (TSRI), and University of California San Diego (UCSD). The Center is co-directed by members of our Operations Team including Drs. Davey Smith (contact PI), Douglas Richman, Robert Schooley, and Bruce Torbett. Our CFAR is comprised of ten Cores and one Scientific Working Group. One of these Cores, the Disparities Core, is completely funded by the California HIV Research Program, but remains ingrained as a standalone Core in our Center. We continue to be guided by our External Advisory and Executive Committees, as well as our Co- Directors, Core Directors, Scientific Working Groups and our membership. Progress: Since our renewal in 2012, these efforts have yielded a productive, enthusiastic and growing group of investigators. As the synergy among our investigators and member institutions increases, we have identified the need to expand our infrastructure to address new opportunities. This success has culminated in our move from a Tier 2 to Tier 3 CFAR.

Public Health Relevance

Overall - The SD CFAR supports basic, clinical, behavioral and translational research programs across our member institutions. These activities add considerable value to NIH funded HIV research. In addition to our active, productive and groundbreaking research, we have a remarkable program for fostering the development of emerging investigators, including scientists new to HIV research.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI036214-25
Application #
9674207
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Wong, Elaine Wai-Ken
Project Start
1997-04-01
Project End
2023-03-31
Budget Start
2019-04-01
Budget End
2020-03-31
Support Year
25
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of California, San Diego
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Prakash, Katya; Gianella, Sara; Dubé, Karine et al. (2018) Willingness to participate in HIV research at the end of life (EOL). PLoS One 13:e0199670
Fraser, Hannah; Mukandavire, Christinah; Martin, Natasha K et al. (2018) Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland. Addiction 113:2118-2131
Macal, Monica; Jo, Yeara; Dallari, Simone et al. (2018) Self-Renewal and Toll-like Receptor Signaling Sustain Exhausted Plasmacytoid Dendritic Cells during Chronic Viral Infection. Immunity 48:730-744.e5
Papasavvas, Emmanouil; Lada, Steven M; Joseph, Jocelin et al. (2018) Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV. AIDS :
Wertheim, Joel O; Murrell, Ben; Mehta, Sanjay R et al. (2018) Growth of HIV-1 Molecular Transmission Clusters in New York City. J Infect Dis 218:1943-1953
Dubé, Karine; Luter, Stuart; Lesnar, Breanne et al. (2018) Use of 'eradication' in HIV cure-related research: a public health debate. BMC Public Health 18:245
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Dubé, Karine; Gianella, Sara; Concha-Garcia, Susan et al. (2018) Ethical considerations for HIV cure-related research at the end of life. BMC Med Ethics 19:83
Chaillon, Antoine; Gianella, Sara; Lada, Steven M et al. (2018) Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc. J Virol 92:
Letendre, Scott; Bharti, Ajay; Perez-Valero, Ignacio et al. (2018) Higher Anti-Cytomegalovirus Immunoglobulin G Concentrations Are Associated With Worse Neurocognitive Performance During Suppressive Antiretroviral Therapy. Clin Infect Dis 67:770-777

Showing the most recent 10 out of 921 publications